Abstract. MicroRNAs (miRs) have been demonstrated to regulate various biological processes in human cancer, including non-small cell lung cancer (NSCLC). However, little evidence has been provided regarding the exact role of miR-200c in mediating the malignant progression of NSCLC, as well as the underlying mechanism. The present study aimed to investigate the putative role of miR-200c in the progression of NSCLC. The expression levels of miR-200c were significantly reduced in NSCLC cell lines compared with in normal lung epithelial cells, as determined by reverse transcription-quantitative polymerase chain reaction. Overexpression of miR-200c significantly suppressed cell migration and invasion of A549 NSCLC cells. Results of a luciferase reporter assay further identified zinc finger E-box-binding homeobox 2 (ZEB2) as a direct target gene of miR-200c, and the expression of ZEB2 was shown to be suppressed in A549 cells overexpressing miR-200c. Furthermore, small interfering RNA-mediated inhibition of ZEB2 suppressed the migration and invasion of A549 cells. In addition, since ZEB2 is an epithelial-mesenchymal transition (EMT) regulator, the role of miR-200c in the regulation of EMT in NSCLC cells was further examined. Results of a western blot analysis indicated that overexpression of miR-200c upregulated E-cadherin, and downregulated N-cadherin and vimentin expression in A549 cells, thus suggesting that EMT was suppressed. Based on these results, the present study suggested that miR-200c was able to inhibit the metastasis of NSCLC cells by targeting ZEB2. Therefore, miR-200c may be considered as a potential candidate for the treatment of NSCLC.
Introduction
Lung cancer is the leading cause of cancer-associated mortality worldwide, the incidence of which is increasing (1) . Non-small cell lung carcinoma (NSCLC) accounts for the majority of lung cancer cases. The majority of cases of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma (2) . Despite great efforts being made regarding the treatment of NSCLC, and recent improvements in surgery, radiotherapy and chemotherapy, the overall survival rate of patients with NSCLC remains poor (1, 3) . Therefore, a more effective therapeutic strategy is urgently required.
MicroRNAs (miRs) are short non-coding RNAs, which can inhibit protein translation, or degrade mRNA by binding to seed sequences within the 3'-untranslational region (UTR) of target mRNAs (4) . It has previously been demonstrated that miRs are important regulators in various biological processes, including cell proliferation, apoptosis, survival, differentiation and motility (5) . Furthermore, several targets of miRs have been reported to be highly associated with tumorigenesis and cancer metastasis (6, 7) . Recent studies have suggested that aberrant expression of miR-200c is associated with the development and progression of NSCLC. Ceppi et al (8) reported that loss of miR-200c expression induces an aggressive, invasive and chemoresistant phenotype in NSCLC. Li et al (9) demonstrated that miR-200c is able to inhibit the invasion and metastasis of NSCLC by directly targeting ubiquitin specific peptidase 25. Furthermore, miR-200c may increase the radiosensitivity of A549 NSCLC cells by targeting the vascular endothelial growth factor (VEGF)-VEGF receptor 2 pathway (10) . Since one miR has several targets, whether other targets of miR-200c are associated with miR-200c-mdiated NSCLC malignant phenotypes remains to be elucidated. Zinc finger E-box-binding homeobox 2 (ZEB2) is a member of the zinc finger homeodomain 1 family of 2-handed zinc finger/homeodomain proteins. It is located in the nucleus and functions as a DNA-binding transcriptional suppressor (11) . ZEB2 has been reported to suppress the expression of E-cadherin, and promote the transcription of vimentin and N-cadherin (11, 12) , thus suggesting that ZEB2 acts as a promoter of epithelial-mesenchymal transition (EMT). Furthermore, ZEB2 has been reported to be involved in the migration, invasion and EMT of NSCLC cells (13) . However, the association between miR-200c and ZEB2 in NSCLC has yet to be studied.
MicroRNA-200c inhibits the metastasis of non
The present study aimed to explore the potential role, as well as the regulatory mechanism, of miR-200c in mediating the metastasis of NSCLC in vitro.
Materials and methods
Cell lines. NSCLC cell lines: A549, H358, H460 and H1229, and the BEAS-2B normal human lung epithelial cell line were obtained from the Chinese Academy of Sciences (Shanghai, China). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.), 100 IU/ml penicillin and 100 IU/ml streptomycin (both purchased from Thermo Fisher Scientific, Inc.) at 37˚C in a humidified atmosphere containing 5% CO 2 .
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. Total RNA was extracted from the cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). For the detection of miR-200c expression, a miRNA Reverse Transcription kit (Thermo Fisher Scientific, Inc.) was used to convert RNA into cDNA, according to the manufacturer's protocol. qPCR was performed using a miRNA Q-PCR Detection kit (Genecopoeia, Rockville, MD, USA) on an Applied Biosystems 7500 thermocycler (Applied Biosystems; Thermo Fisher Scientific, Inc.). The final reaction volume was 20 µl, including 1 µl cDNA, 10 µl PCR Master Mix (GeneCopoeia), 2 µl primer and 7 µl H 2 O. The PCR conditions were as follows: 95˚C for 5 min, and 40 cycles of denaturation at 95˚C for 15 sec and annealing/elongation at 60˚C for 30 sec. Primers were purchased from Sangon Biotech Co., Ltd. (Shanghai, China) and the sequences were as follows: miR-200x Forward, 5'-CTT AAA GCC CCT TCG TCTCC-3' and reverse, 5'-AGG GGT GAA GGT CAG AGGTT-3'; and U6 forward, 5'-TGC GGG TGC TCG CTT CGG CAGC-3' and reverse, 5'-CCA GTG CAG GGT CCG AGGT-3'. U6 gene was used as an internal reference. The relative expression levels were analyzed using the 2 -ΔΔCq method (14) .
Transfection. Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used to conduct transfection of the cells, according to the manufacturer's protocol. miR-200c mimic, scramble mimic, miR-200c inhibitor (Shanghai Genechem Co., Ltd., Shanghai, China) ZEB2 small interfering (si)RNA or negative control siRNA and Lipofectamine ® 2000 were diluted in ser um-f ree DM EM. T he diluted Lipofectamine 2000 was added to the diluted miR mimic or siRNA (100 nM). Following a 20 min incubation at room temperature, the mixture was added to a cell suspension (5,000,000 cells/ml). Following a 10 h incubation at 37˚C in an atmosphere containing 5% CO 2 , the medium was replaced with DMEM supplemented with 10% FBS.
Western blot analysis. Cells were lysed with ice-cold lysis buffer [50 mM Tris-HCl, pH 6.8; 100 mM 2-ME, 2%w/v sodium dodecyl sulfate (SDS), 10% glycerol]. Proteins (50 µg) were separated by 10% SDS-polyacrylamide gel electrophoresis, and were then transferred onto a polyvinylidene difluoride (PVDF) membrane (GE Healthcare Life Sciences, Chalfont, UK). The PVDF membrane was then blocked with phosphate-buffered saline (Thermo Fisher Scientific, Inc.) containing 5% milk overnight at 4˚C, and was incubated with rabbit anti-ZEB2 polyclonal antibody (1:200; ab138222; Abcam, Cambridge, MA, USA), rabbit anti-E-cadherin monoclonal antibody (1:200; ab15148; Abcam), rabbit anti-vimentin monoclonal antibody (1:100; ab92547; Abcam), rabbit anti-N-cadherin polyclonal antibody (1:200; ab12221; Abcam), and rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) polyclonal antibodies (1:200; ab9485; Abcam) at room temperature for 3 h. Subsequently, the membrane was incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:10,000; ab150077; Abcam) at room temperature for 1 h. The signals on the PVDF membrane were detected using the Super Signal West Pico Chemiluminescent Substrate kit (Pierce Biotechnology, Inc., Rockford, IL, USA), according to the manufacturer's protocol. Protein concentration was quantified using a BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's instruction. The relative protein expression levels were analyzed using Image-Pro Plus software 6.0 (National Institutes of Health, Bethesda, MD, USA), and are presented as the density ratio vs. GAPDH.
Cell migration assay. A549 NSCLC cells were cultured to full confluence in 6-well plates, and wounds (width, 1 mm) were created using a plastic scriber. Cells were washed and incubated in DMEM containing10% FBS at 37˚C in an atmosphere containing 5% CO 2 for 48 h. Subsequently, the cells were fixed with methanol and observed using a microscope (CX31; Olympus Corporation, Tokyo, Japan).
Cell invasion assay. Cell invasion assay was performed using Transwell chambers pre-coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). An A549 cell suspension containing 5x10 5 cells/ml was prepared in serum-free DMEM, and 300 µl cell suspension was added to the upper chamber. A total of 500 µl DMEM supplemented with 10% FBS was added to the lower chamber. Following a 24 h incubation at 37˚C in an atmosphere containing 5% CO 2 , the A549 cells that did not invade through the membrane were removed from the chamber with a cotton-tipped swab. The upper chamber was then fixed in 90% alcohol and stained with 0.1% crystal violet. A549 cells that had invaded through the membrane were observed under an inverted microscope (CX31; Olympus Corporation).
Luciferase reporter gene assay. Total cDNA from A549 cells was used to amplify the 3'UTR of ZEB2 using PCR, which was then cloned into the pMir-Report vector (Thermo Fisher Scientific, Inc.), resulting in the generation of pMIR-ZEB2. Mutations were introduced within the seed sequences of the 3'UTR of ZEB2 using the QuikChange Site-Directed Mutagenesis kit (Stratagene; Agilent Technologies, Inc., Santa Clara, CA, USA). The mutated ZEB2 3'UTR was then cloned into the pMir-Report vector, generating pMIR-Mut ZEB2. A549 NSCLC cells were co-transfected with 100 ng pMIR-ZEB2 or pMIR-ZEB2-Mut vector and 100 mM miR-200c mimic or scramble miR mimic, and the pRL-TK plasmid (Promega Corporation, Madison, WI, USA) for internal normalization. Following a 36 h incubation at 37˚C in an atmosphere containing 5% CO 2 , the cells were lysed using lysis buffer (Promega Corporation), and the Dual-Luciferase Reporter Assay system (Promega Corporation) was used to conduct luciferase reporter gene assay on an LD400 luminometer (Beckman Coulter, Brea, CA, USA), according to the manufacturer's protocol. Data are presented as the ratio of Renilla luciferase to firefly luciferase.
Statistical analysis. Data are presented as the mean ± standard deviation from at least three separate experiments. SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Differences between the groups were determined using one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.
Results

miR-200c is significantly downregulated in NSCLC cell lines.
RT-qPCR was conducted to detect the expression levels of miR-200c in the following NSCLC cell lines: A549, H358, H460 and H1229, and in the BEAS-2B normal human lung epithelial cell line, which was used as a control. The expression levels of miR-200c were significantly reduced in the NSCLC cell lines compared with in the BEAS-2B cells. The A549 cells exhibited the most significant decrease in the expression levels of miR-200c (P<0.05; Fig. 1 ). 
Overexpression of miR-
ZEB2 is a direct target of miR-200c in NSCLC cells.
Three computational algorithms: PicTar (http://pictar.mdc-berlin. de/), TargetScan (http://www.targetscan.org/), and miRanda (http://www.microrna.org/microrna/home.do), were used to search for potential target genes of miR-200c. Among all putative targets of miR-200c, ZEB2 was evolutionarily conserved, and perfect base pairing was observed between the seed sequence of mature miR-200c and the 3'UTR of ZEB2 mRNA (Fig. 3A) . Total cDNA from A549 cells was used to amplify the 3'UTR of ZEB2, which was then cloned into the pMir-Report vector, generating pMIR-ZEB2. In addition, mutations were introduced within the seed sequences of the 3'UTR of ZEB2 (Fig. 4A) , and were then cloned into the pMir-Report vector, generating pMIR-Mut ZEB2. Subsequently, a luciferase reporter assay was used to determine whether miR-200c was able to directly bind to seed sequences in the ZEB2 3'UTR in NSCLC A549 cells. As shown in Fig. 3B , the luciferase activity was markedly reduced in A549 cells co-transfected with pMIR-ZEB2 and miR-200c mimic (P<0.05); however, no difference was detected in the A549 cells co-transfected with pMIR-Mut ZEB2 and miR-200c mimic, as compared with the control group. These findings indicate that ZEB2 is a direct target of miR-200c in NSCLC cells.
The present study also determined the protein expression levels of ZEB2 in A549 cells following upregulation or downregulation of miR-200c. As shown in (15) reported that miR-200c was frequently upregulated in NSCLC tissues, and high expression of miR-200c was associated with a poor survival in patients with NSCLC. Furthermore, high miR-200c expression was correlated with shorter overall survival in NSCLC adenocarcinoma, but not in squamous cell carcinoma, thus suggesting a dual role for miR-200c in the prognosis of NSCLC, which may be associated with tumor cell origin (16) .
The present study identified ZEB2 as a direct target gene of miR-200c, and demonstrated that miR-200c negatively regulates the protein expression of ZEB2 in A549 NSCLC cells. ZEB2 is a member of the deltaEF-1 family of two-handed zinc-finger factors, and acts as a transcriptional suppressor (17) . ZEB2 has been demonstrated to be associated with various types of human cancer, including gastric cancer (18) , renal cell carcinoma (19) , ovarian cancer (20) , glioma (21), pancreatic cancer (22) , and lung cancer (23). Fang et al (23) demonstrated that overexpression of ZEB2 was associated with poor pathological stage of small cell lung cancer and shorter survival time, whereas knockdown of ZEB2 sensitized cancer cells to chemotherapeutic drugs by increasing drug-induced cell apoptosis and inducing an S phase cell cycle arrest. These results suggested that ZEB2 acts as an oncogene in lung cancer. In the present study, knockdown of ZEB2 significantly suppressed the migration, invasion and EMT of NSCLC cells, similar effects to those observed following miR-200c overexpression. In addition, ZEB2 has been identified as a direct target of miR-200c in other cancer types. Gregory et al (24) reported that the miR-200 family (miR-200a, miR-200b, miR-200c , miR-141 and miR-429) and miR-205 were able to suppress EMT in invasive breast cancer cell lines with mesenchymal phenotypes by directly targeting ZEB2. Therefore, the present study provides further evidence regarding the relationship between miR-200c and ZEB2 in human cancer.
In conclusion, the present study demonstrated that miR-200c exerts suppressive effects on the migration, invasion and EMT of NSCLC cells, at least partly by targeting ZEB2, thus suggesting that miR-200c acts as a tumor suppressor in NSCLC metastasis. Therefore, miR-200c may be used for the prevention of NSCLC metastasis.
